While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...

Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with a 33% revenue growth and outlines strategic ...

While such combinations may face reimbursement challenges in the near term, they could represent a significant opportunity for Alnylam as the ATTR-CM treatment paradigm evolves. Alnylam's near ...

amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

The company is also advancing its engineered stem cell antibody paired evasion (ESCAPE) conditioning strategy to face the toxicity ... indications like ATTR amyloidosis and hereditary angioedema.

It is worth noting, however, that Attruby may be required to face off against another ... mediated (hATTR) amyloidosis in adults - in the indication of ATTR-CM, setting a decision date of March ...

Smaller and mid-tier stocks did face challenges in prior years when ... It treats transthyretin amyloid cardiopathy (ATTR-CM). This approval took effect in late 2024. The commercial uptake so ...